medic
intervent
dramat
increas
last
centuri
case
infecti
diseas
discoveri
develop
antibiot
antivir
agent
repres
power
extern
select
constraint
impos
upon
replic
microb
hundr
antivir
agent
develop
sinc
second
half
centuri
virus
gener
find
evolutionari
pathway
continu
replic
presenc
true
antibiot
replic
bacteria
belief
bacteri
diseas
way
toward
extinct
quit
widespread
middl
centuri
sir
burnet
wrote
textbook
sinc
bacteri
infect
unimport
except
amen
treatment
one
new
drug
real
problem
like
concern
viru
diseas
burnet
promin
spanish
medic
doctor
g
declar
year
cancer
histor
diseas
infect
almost
entir
absent
caus
mortal
person
note
join
univers
california
irvin
work
postdoctor
student
rc
warner
attend
biolog
cours
teacher
express
student
infecti
diseas
would
disappear
decad
consequ
use
antibiot
antivir
agent
predict
scienc
tend
fail
optimist
view
unanim
fleme
discover
penicillin
recogn
adapt
capac
bacteria
suggest
viru
popul
http
bacteria
would
inevit
find
way
resist
damag
caus
antimicrobi
drug
quot
document
new
antimicrobi
drug
european
academi
scienc
advisori
council
novemb
wwweasaceu
see
also
chapter
furthermor
earli
evid
select
mycobacterium
tuberculosi
mutant
resist
streptomycin
mitchison
antibiot
resist
bacteria
similar
differ
antivir
resist
virus
compar
chapter
awar
one
major
problem
antivir
therapi
nearli
systemat
select
drugresist
viru
mutant
often
associ
treatment
failur
extern
influenc
vaccin
immunotherapi
particularli
use
monoclon
antibodi
also
evok
select
viral
subpopul
capabl
replic
presenc
compon
inher
immun
respons
thu
select
constraint
intend
limit
rna
viru
replic
meet
broad
dynam
repertoir
variant
ingrain
quasispeci
dynam
two
spacetim
level
effect
drug
vaccin
distinguish
come
section
shortterm
consequ
individu
form
treatment
vaccin
failur
ii
longterm
consequ
popul
level
field
vaccinedriven
evolut
antigen
properti
virus
medic
intervent
may
alter
viru
surviv
individu
immunocompromis
consequ
treatment
organ
transplant
subject
anticanc
chemotherapi
becom
particularli
vulner
viral
infect
enhanc
viral
replic
favor
patholog
manifest
affect
individu
well
spread
larg
number
virus
environ
consequ
emerg
reemerg
viral
diseas
section
chapter
viral
diseas
import
burden
human
health
agricultur
bloom
lambert
viru
evolut
basic
mechan
expos
previou
chapter
influenc
two
major
strategi
combat
viral
infect
prevent
vaccin
treatment
antivir
inhibitor
design
new
antivir
vaccin
critic
issu
divers
display
field
viru
control
natur
evolut
viru
may
result
circul
one
major
antigen
type
cocircul
multipl
antigen
form
vaccin
composit
independ
type
vaccin
see
section
must
match
antigen
composit
viru
control
hepat
viru
hav
circul
singl
serotyp
footandmouth
diseas
viru
fmdv
circul
seven
serotyp
divers
subtyp
antigen
type
unevenli
distribut
differ
geograph
locat
monoval
vaccin
made
prevail
antigen
type
hav
suffici
confer
protect
multival
vaccin
compos
sever
type
subtyp
requir
confer
protect
fmdv
antigen
composit
vaccin
match
circul
virus
geograph
region
antifmd
vaccin
differ
composit
use
differ
world
area
given
time
vaccin
composit
must
period
updat
maintain
efficaci
thu
one
effect
viru
evolut
relev
vaccin
design
deriv
necess
prepar
vaccin
mirror
antigen
composit
viru
control
case
liveattenu
antivir
vaccin
evolut
vaccin
viru
replic
vaccine
risk
factor
produc
virul
deriv
invas
suscept
host
viru
ensu
viral
replic
regard
stepwis
process
viru
must
adapt
seri
select
pressur
present
host
notabl
immun
respons
outcom
either
viral
clearanc
elimin
infect
viru
surviv
progress
toward
acut
persist
infect
administr
antivir
agent
addit
select
constraint
limit
viral
replic
evolutionari
mechan
may
either
succeed
select
mutant
resist
antivir
agent
permit
infect
continu
fail
sustain
infect
result
clear
viru
organ
treatment
plan
one
aim
new
antivir
pharmacolog
intervent
base
inform
viral
genom
sequenc
present
infect
patient
parallel
vaccin
composit
design
vaccin
inform
come
analys
antigen
composit
circul
virus
antivir
agent
inform
come
mutant
spectrum
composit
viru
control
infect
patient
worldwid
vaccin
campaign
made
possibl
erad
human
smallpox
offici
declar
world
health
organ
anim
rinderpest
offici
declar
world
organ
anim
health
offic
intern
de
epizooti
oie
number
new
case
decreas
result
vaccin
program
sever
viral
diseas
includ
measl
hepat
b
bloom
lambert
substanti
progress
made
toward
erad
poliomyel
chumakov
kew
himman
deliber
decis
vaccin
religi
reason
misinform
campaign
lack
vaccin
access
socioeconom
circumst
jeopard
vaccin
efficaci
fact
demonstr
least
viral
diseas
control
global
basi
vaccin
unpreced
achiev
human
anim
health
despit
huge
econom
invest
howev
import
viral
diseas
acquir
immunodefici
syndrom
aid
hepat
c
viral
hemorrhag
fever
effect
vaccin
avail
diseas
human
influenza
anim
fmd
vaccin
access
requir
period
updat
approxim
antigen
composit
vaccin
circul
viru
section
case
influenza
viru
iv
major
chang
antigen
composit
occur
antigen
shift
viru
acquir
new
hemagglutinin
neuraminidas
gene
genom
segment
reassort
section
chapter
first
evid
obtain
g
laver
earli
earli
histori
influenza
caus
viru
vaccin
design
see
beveridg
kilbourn
antigen
variat
virus
whatev
mechan
might
affect
vaccin
efficaci
case
extrem
rapid
intra
interhost
evolut
viru
may
render
effect
vaccin
unfeas
least
current
tool
vaccinolog
cell
respons
may
act
soon
infect
promot
select
escap
mutant
bull
et
al
difficulti
control
viru
diseas
deriv
adapt
potenti
virus
domingo
domingo
holland
bailey
et
al
hamelaar
et
al
requir
judici
applic
exist
tool
innov
approach
still
infanc
first
basic
requisit
prepar
vaccin
viral
agent
understand
antivir
vaccin
adapt
potenti
virus
immun
respons
evok
viru
infect
organ
protect
activ
b
lymphocyt
antibodi
product
cellular
respons
gener
memori
cell
correl
protect
bloom
lambert
van
regenmortel
hagan
et
al
cunningham
et
al
rolland
despit
social
pressur
rapidli
obtain
vaccin
virushost
system
welldesign
experi
necessari
tri
establish
determin
protect
simpl
issu
discuss
come
paragraph
focus
relev
viru
evolut
vaccin
efficaci
irrespect
type
protect
afford
vaccin
term
protect
may
mean
total
absenc
replic
infect
viru
term
steril
immun
absenc
diseas
manifest
despit
infect
viru
replic
gener
initi
statement
wide
accept
vaccinologist
vaccin
like
effect
evok
immun
respons
similar
respons
elicit
authent
viral
pathogen
produc
diseas
success
overcom
infect
organ
evan
kaslow
bloom
lambert
refer
basic
principl
vaccinolog
infect
antigen
constant
viru
produc
lifelong
immun
ie
measl
viru
infect
vaccin
like
evok
longlast
protect
contrast
patient
cure
viru
reinfect
close
relat
viru
ie
hepat
c
viru
infect
vaccinedat
least
one
prepar
standard
methodologydi
unlik
evok
protect
point
consid
design
antivir
vaccin
list
box
intend
minim
select
vaccineescap
mutant
favor
success
vaccin
campaign
recommend
deserv
comment
first
basic
knowledg
viru
evolutionari
dynam
affect
viru
antigen
stabil
lack
essenti
fact
methodolog
avail
ie
vector
express
larg
amount
base
domingo
holland
quasispeci
dynam
diseas
prevent
control
antigen
display
good
immunogen
guarante
vaccin
efficaci
even
less
correl
protect
understood
order
efficaci
differ
vaccin
design
propos
box
justifi
basic
principl
vaccinolog
mechan
select
antibodi
ab
cytotox
tcell
ctl
escap
mutant
virus
singl
amino
acid
substitut
band
tcell
epitop
viral
protein
often
suffici
elud
neutral
correspond
cognatespecif
antibodi
escap
recognit
clonal
ctl
popul
mani
virus
frequenc
monoclon
antibodyescap
mutant
measur
even
clonal
popul
obtain
control
laboratori
condit
undergon
limit
number
replic
round
section
chapter
gener
immuneescap
variant
result
lack
vaccin
efficaci
contribut
viral
persist
pircher
et
al
weidt
et
al
ciurea
et
al
ciurea
et
al
richman
et
al
pawlotski
provok
vaccinationinduc
viru
evolut
section
human
immunodefici
viru
type
antibodyescap
variant
incessantli
produc
vivo
point
viru
replic
continu
despit
antibodi
respons
richman
et
al
bailey
et
al
frequenc
select
mutant
escap
number
n
compon
could
hypothet
separ
global
immun
respons
far
lower
frequenc
escap
singl
b
c
etc
compon
respons
make
simpl
mathemat
abstract
applic
also
antiviralescap
mutant
section
frequenc
mutant
escap
n
compon
immun
respons
product
frequenc
escap
individu
compon
oversimplif
realist
dissect
select
impact
complex
immun
respons
discret
compon
viru
gener
includ
multipl
antigen
site
often
compos
sever
overlap
nonoverlap
epitop
addit
viru
sever
tcell
epitop
differ
structur
nonstructur
protein
epitop
display
differ
degre
rel
domin
howev
abstract
reflect
advantag
stimul
host
immun
system
suffici
broad
array
band
tcell
epitop
prevent
select
vaccineescap
mutant
due
high
genet
phenotyp
barrier
compar
barrier
drug
resist
describ
section
therefor
select
vaccineescap
viral
mutant
like
synthet
peptid
vaccin
whole
virusattenu
inactiv
vaccin
latter
present
broad
epitop
repertoir
immun
system
select
escapemut
peptid
vaccin
evok
partial
protect
cattl
document
fmdv
taboga
et
al
tami
et
al
argument
favor
multiepitop
present
also
endors
notori
scarciti
licens
peptid
vaccin
viral
diseas
despit
horrend
econom
invest
order
magnitud
greater
invest
quasispeci
research
use
complex
multiepitop
vaccin
howev
need
prevent
longterm
select
antigen
viru
variant
result
vaccin
usag
import
still
larg
underexplor
topic
discuss
section
experiment
evolut
fmdv
open
way
new
gener
antivir
vaccin
share
featur
attenu
inactiv
vaccin
new
design
base
convers
monopartit
fmdv
genom
segment
genom
version
domin
popul
extens
high
moi
passag
section
chapter
section
chapter
segment
viru
version
abl
produc
progeni
two
genom
class
encapsid
separ
particl
must
reach
cell
therefor
administr
segment
viru
prepar
lead
antivir
vaccin
adapt
potenti
virus
immun
respons
akin
evok
inactiv
viral
particl
follow
selflimit
infect
vaccin
test
success
mice
swine
authent
host
parent
viru
rodriguezcalvo
et
al
potenti
concern
type
vaccin
standard
monopartit
genom
reconstruct
recombin
earli
stage
replic
anim
safeti
level
includ
particular
fmd
vaccin
multipl
mutat
accumul
transit
toward
genom
segment
deviat
genom
sequenc
one
present
origin
swine
isol
explor
evolutionari
mechan
result
alter
form
virus
may
open
new
possibl
vaccin
design
new
prospect
attenu
vaccin
open
engin
virus
suboptim
replic
fidel
deoptim
codon
codon
pair
usag
coleman
et
al
vignuzzi
et
al
cheng
et
al
alter
polymeras
copi
fidel
often
lead
viru
attenu
gnadig
et
al
graham
et
al
korbouk
et
al
rozengagnon
et
al
van
slyke
et
al
critic
issu
liveattenu
vaccin
base
deviat
standard
mutat
rate
stabil
attenu
trait
true
revert
site
revert
polymeras
may
aris
displac
vaccin
viru
viral
protein
may
affect
nucleotid
incorpor
smith
et
al
stapleford
et
al
agudo
et
al
viru
circul
popul
vaccin
unvaccin
host
individu
coexist
vaccin
induc
steril
immun
virus
alter
antigen
profil
might
select
larger
overal
effect
popul
size
circul
viru
longer
viru
allow
replic
scenario
higher
probabl
incorpor
compensatori
mutat
yield
highfit
antigen
variant
event
case
vaccin
use
veterinari
medicin
particularli
signific
may
alter
cell
tropism
host
rang
virus
thu
increas
possibl
zoonot
transmiss
human
schat
baranowski
evid
vaccinationinduc
dna
rna
viru
evolut
increas
document
bovin
respiratori
syncyti
viru
bovin
marek
diseas
viru
porcin
circoviru
classic
swine
fever
viru
among
other
valarch
et
al
muylken
et
al
ji
et
al
kekarainen
et
al
constan
et
al
yoo
et
al
review
gandon
et
al
schat
baranowski
time
domin
ctlescap
mutant
simian
immunodefici
viru
siv
influenc
vaccin
process
could
analyz
penetr
mutant
spectra
relev
viral
popul
loh
et
al
human
virus
evid
vaccineescap
mutant
obtain
hepat
b
virus
vaccinationassoci
escap
mutant
hav
substitut
around
immunodomin
site
viru
identifi
cohort
hav
doubli
infect
individu
perezsautu
et
al
studi
suggest
incomplet
vaccin
schedul
combin
immunosuppress
might
contribut
highhav
load
thu
facilit
gener
domin
antigen
variant
taiwan
preval
mutant
major
antigen
determin
surfac
antigen
hepat
b
viru
hbv
tripl
decad
suggest
increas
preval
might
due
ampl
vaccin
coverag
region
hsu
et
al
studi
also
suggest
circul
hbv
mutant
quasispeci
dynam
diseas
prevent
control
associ
vaccin
escap
diagnosi
failur
di
lello
et
al
vaccin
rare
afford
protect
vaccin
individu
due
mani
factor
includ
variat
vaccin
recept
factor
due
polymorph
gene
involv
adapt
immun
respons
immunosuppress
vaccin
recipi
insuffici
time
vaccin
exposur
viral
pathogen
antigen
differ
vaccin
strain
circul
virus
addit
massiv
vaccin
veterinari
medicin
damag
vaccin
transport
storag
etc
improp
administr
addit
problem
vaccin
may
occasion
promot
select
antigen
variant
also
host
cell
tropism
host
rang
virul
variant
swayn
kapczynski
kirkwood
read
et
al
rolland
known
extent
widespread
use
vaccin
contribut
antigen
variat
rel
factor
persist
antibodi
previou
infect
genet
drift
due
genet
bottleneck
etc
howev
current
understand
viru
dynam
encourag
investig
genet
antigen
modif
breakthrough
virus
aris
vaccin
individu
compar
chang
virus
unvaccin
host
popul
revers
liveattenu
vaccin
virus
virul
form
caus
diseas
deriv
evolutionari
potenti
virus
case
attenu
sabin
polioviru
vaccin
rate
vaccineassoci
poliomyel
among
vaccin
first
time
one
per
vaccine
rate
receiv
second
vaccin
dose
one
million
review
rowland
minor
attenu
antifmd
vaccin
use
countri
second
half
centuri
revers
virul
forc
halt
vaccin
program
vaccineescap
mutant
may
aris
due
ineffect
vaccin
concomit
factor
immunosuppress
escap
mutant
may
remain
confin
unsuccess
vaccin
host
may
spread
suscept
individu
attain
differ
degre
epidemiolog
relev
escap
mutant
may
direct
mutant
infect
viru
may
origin
recombin
infect
viru
coinfect
relat
virus
observ
polioviru
bovin
kew
et
al
thiri
et
al
among
studi
reiter
vaccin
select
fit
increas
process
mani
gener
vaccine
human
anim
may
result
acceler
viru
evolut
sinc
systemat
use
vaccin
human
anim
intens
product
unit
rel
recent
term
evolutionari
time
less
year
case
even
decad
still
prematur
evalu
whether
vaccin
signific
factor
promot
longterm
viru
evolut
first
descript
viru
resist
antivir
inhibitor
j
barreraoro
hj
egger
tamm
colleagu
work
enterovirus
guanidin
hydrochlorid
alphahydroxybenzyl
benzimidazol
inhibitor
egger
tamm
melnick
et
al
earli
result
suggest
antiviralresist
mutant
could
readili
select
ampli
confirm
mani
virus
inhibitor
cell
cultur
vivo
inde
select
viral
mutant
resist
antivir
agent
extrem
frequent
occurr
known
decad
although
becam
wide
recogn
cours
develop
clinic
use
antiretrovir
agent
treat
infect
aid
descript
drugescap
mutant
base
three
main
group
observ
detect
antiviralresist
mutant
patient
treatment
revers
genet
system
avail
suspect
mutat
introduc
infecti
clone
resist
ascertain
quantifi
cell
cultur
vitro
enzym
assay
select
resist
mutant
cell
cultur
subject
virus
passag
presenc
inhibitor
viral
popul
size
import
variabl
type
experi
section
calcul
frequenc
resist
mutant
plate
viru
absenc
presenc
antivir
agent
similar
assay
calcul
frequenc
monoclon
antibodi
mab
resist
mutant
describ
chapter
section
three
group
observ
frequenc
specif
escap
mutant
found
depend
number
barrier
resist
section
tradit
fact
drug
select
virusresist
mutant
regard
proof
select
drug
oppos
unspecif
toxic
effect
host
cell
indirectli
impair
viru
replic
herrmann
herrmann
golan
tashjian
select
viral
mutant
resist
antivir
inhibitor
major
problem
control
viral
diseas
two
main
reason
often
result
viru
breakthrough
increas
viral
load
result
treatment
failur
ii
resist
viru
variant
may
becom
epidemiolog
relev
consequ
decreas
inhibitor
efficaci
popul
level
domingo
holland
huang
et
al
increas
number
antivir
agent
develop
base
threedimension
structur
viral
protein
complex
natur
synthet
ligand
effort
engag
academ
institut
pharmaceut
compani
other
incorpor
result
drug
reposit
discoveri
antivir
activ
compound
licens
medic
purpos
often
help
comput
tool
ab
ghani
et
al
antivir
agent
may
target
viral
cellular
protein
involv
step
viru
life
cycl
may
interact
virion
inhibit
earli
step
infect
attach
host
cell
penetr
cell
uncoat
liber
genet
materi
viru
insid
cell
agent
interfer
synthesi
viral
nucleic
acid
viral
protein
process
particl
assembl
viru
releas
cell
select
resist
mutant
describ
virtual
chemic
type
antivir
agent
direct
step
infecti
cycl
dna
rna
virus
includ
import
pathogen
herpesvirus
picornavirus
iv
hbv
hepat
c
viru
hcv
sever
review
articl
cover
theoret
basi
drug
resist
consequ
treatment
manag
exampl
see
domingo
et
al
previou
version
progress
drug
research
richman
richman
ribeiro
bonhoeff
domingo
et
al
domingo
et
al
menendezaria
peral
mokaya
et
al
nitta
et
al
pawlotski
articl
current
opinion
virolog
volum
edit
l
menendezaria
richman
menendezaria
richman
therefor
gener
mechan
confer
adapt
virus
effect
find
drugescap
pathway
molecular
mechan
summar
section
consid
implic
quasispeci
dynam
explain
previou
chapter
quasispeci
dynam
diseas
prevent
control
follow
statement
obviou
reader
singl
mutat
abl
confer
resist
antivir
agent
mutat
caus
signific
select
disadvantag
viru
fit
decreas
consid
environ
drugresist
viru
mutant
present
viru
popul
domingo
viru
replic
way
popul
size
never
achiev
singl
popul
extrem
unlik
drugresist
mutat
mutat
associ
phenotyp
chang
gener
frequenc
lower
propag
viral
popul
peral
et
al
select
escap
mutant
depend
replic
load
concentr
inhibitor
attain
site
viru
replic
consid
differ
cell
tissu
compart
antivir
inhibitor
reach
differ
concentr
exert
differ
intens
select
fig
compart
multipl
replic
complex
mutat
confer
resist
inhibitor
occur
rate
assum
mutat
rate
independ
presenc
inhibitor
howev
occurr
proport
viral
rna
harbor
mutat
decreas
depend
inhibitor
concentr
time
effect
inhibitor
manifest
depend
inhibitor
target
exampl
fig
assum
concentr
inhibitorresist
mutant
decreas
replic
complex
reach
resist
mutant
frequenc
compart
respect
frequenc
inhibitorresist
mutant
entir
cell
tissu
organ
time
given
weight
averag
mutat
frequenc
individu
compart
case
virusproduc
viremia
assum
bottleneck
effect
differenti
select
figur
frequenc
drugresist
mutant
differ
compart
subcellular
site
cell
tissu
organ
organ
three
compart
label
three
drawn
replic
complex
depict
ellips
replic
genom
line
replic
unit
defin
set
replic
complex
inhibitorresist
mutant
repres
red
circl
genom
compart
reach
increas
concentr
inhibitor
render
inhibitorresist
mutant
frequenc
respect
see
text
differ
occurr
presenc
resist
mutant
implic
compartment
resist
antivir
inhibitor
trait
frequenc
resist
mutant
calcul
viru
blood
reflect
averag
frequenc
compart
suppli
viru
blood
low
inhibitor
concentr
compart
favor
select
resist
mutant
either
archiv
adapt
reservoir
penetr
compart
depend
sequenc
event
viru
spread
two
independ
mutat
confer
resist
inhibitor
probabl
occurr
inhibitorresist
mutant
equal
sum
probabl
occurr
mutat
multipl
mutat
probabl
sum
probabl
differ
mutat
frequent
case
virus
sinc
often
display
sever
evolutionari
pathway
drug
resist
probabl
find
viral
genom
resist
two
inhibitor
direct
differ
target
given
product
probabl
resist
individu
inhibitor
basic
probabl
consider
regard
frequenc
occurr
inhibitorresist
viral
mutant
summar
box
two
mutat
occur
genom
may
subject
epistat
effect
mean
either
increas
posit
epistasi
decreas
neg
epistasi
viral
fit
see
section
chapter
concept
epistasi
divers
chemic
structur
antivir
compound
select
escap
mutant
illustr
fig
formula
antivir
agent
current
histor
use
includ
rel
simpl
organ
molecul
nucleosid
analog
complex
heterocycl
compound
varieti
residu
ch
nh
nh
f
cl
may
contribut
interact
viral
protein
alter
electron
structur
neighbor
bond
thu
modifi
interact
behavior
atom
resist
viral
mutant
identifi
despit
barrier
impos
upon
viru
reach
drugresist
phenotyp
two
differ
mutat
produc
inhibitorresist
phenotyp
one
mutat
present
addit
mutat
longer
necessari
produc
phenotyp
probabl
achiev
phenotyp
chang
equal
sum
probabl
find
mutat
individu
two
independ
mutat
must
happen
produc
resist
inhibitor
probabl
occurr
necessari
mutat
equal
product
probabl
occurr
mutat
individu
viru
inhibit
inhibitor
combin
mutat
confer
resist
inhibitor
independ
crossresist
involv
probabl
combinationresist
mutant
aris
equal
product
probabl
resist
individu
mutat
probabl
calcul
applic
mutationdepend
viru
variat
impedi
viru
attain
resist
inhibitor
divid
genet
phenotyp
mutant
swarm
popul
barrier
resist
box
genet
barrier
resist
specif
inhibitor
univers
valu
viru
group
sinc
may
affect
genet
differ
among
natur
viral
isol
diversif
hcv
genotyp
influenc
genet
barrier
resist
proteas
inhibitor
telaprevir
formula
fig
one
amino
acid
substitut
confer
resist
telaprevir
genotyp
triplet
encod
aga
therefor
singl
nucleotid
transit
g
yield
triplet
aaa
encod
k
genotyp
triplet
encod
cga
therefor
two
nucleotid
chang
transvers
c
transit
g
requir
reach
aaa
triplet
encod
k
reach
altern
aag
codon
k
would
requir
larger
number
mutat
see
section
chapter
anoth
exampl
synonym
codon
usag
influenc
rimantadin
methylamin
oseltamivir
trade
name
tamiflu
ethyl
zanamivir
trade
name
relenza
acid
resist
antivir
inhibitor
figur
inhibitor
human
immunodefici
viru
type
antiretrovir
agent
hepat
c
viru
inhibitor
zidovudin
azt
hydroxymethyl
zalcitabin
ddc
hydroxymethyl
one
methoxyphenoxyphosphoryl
amino
propano
addit
drug
current
use
antivir
therapi
found
refer
quot
text
chapter
quasispeci
dynam
diseas
prevent
control
evolutionari
outcom
requir
transit
versu
transvers
reach
resist
phenotyp
affect
genet
barrier
resist
viral
polymeras
tend
produc
transit
mutat
readili
transvers
presum
cours
rna
elong
easier
misincorpor
purin
anoth
purin
pyrimidin
pyrimidin
misincorpor
chapter
mutat
prefer
one
sever
factor
determin
frequenc
drugescap
mutant
thu
evolut
may
diversifi
virus
display
differ
genet
barrier
drug
sinc
mani
case
sever
independ
mutat
may
confer
resist
drug
complic
matter
even
also
consid
genet
barrier
one
inhibitor
may
affect
presenc
inhibitor
beerenwinkel
et
al
phenotyp
barrier
drug
resist
equival
fit
cost
inflict
upon
viru
mutat
correspond
amino
acid
substitut
requir
resist
fit
cost
treat
chapter
section
chapter
section
connect
frequenc
monoclon
antibodyor
cytotox
tcellescap
mutant
viral
popul
drugresist
mutat
inflict
high
fit
cost
like
result
revers
mutat
viru
replic
absenc
drug
altern
outcom
compensatori
mutat
introduc
genom
viral
fit
increas
maintain
inhibitorresist
mutat
two
outcom
mutual
exclus
may
contribut
multipl
transient
select
pathway
observ
applic
deep
sequenc
monitor
respons
viral
popul
specif
select
forc
tsibri
et
al
fischer
et
al
cale
et
al
kortenhoeven
et
al
see
section
chapter
high
fit
cost
may
prevent
delay
select
escap
mutant
sofosbuvir
formula
fig
effect
viral
polymeras
inhibitor
hcv
amino
acid
substitut
associ
sofosbuvir
resist
substitut
detect
patient
natur
isol
hcv
one
sever
clinic
studi
sofosbuvir
efficaci
mutant
spectrum
composit
hcv
genotyp
infect
patient
treat
drug
follow
deep
sequenc
viru
baselin
prior
initi
treatment
cours
treatment
posttreat
frequenc
baselin
indic
preexist
resist
mutat
despit
exposur
viru
drug
section
two
day
initi
sofosbuvir
treatment
level
decreas
viral
breakthrough
detect
week
later
viral
popul
includ
posttreat
period
genom
wildtyp
amino
acid
regain
domin
attribut
true
revers
mutant
genom
rather
outgrowth
baselin
wildtyp
genom
hedskog
et
al
result
suggest
high
phenotyp
barrier
sofosbuvir
hcv
mechan
overcom
barrier
complex
virushost
interact
render
elucid
pathway
exploit
viru
overcom
phenotyp
barrier
drug
highli
empir
endeavor
hope
combin
inhibitor
display
high
barrier
resist
may
imped
escap
drive
viru
extinct
chapter
mutant
swarm
barrier
resist
consequ
interf
interact
oper
within
quasispeci
describ
chapter
section
particular
case
interfer
delay
imped
increas
frequenc
resist
mutat
crowder
kirkegaard
kirkegaard
et
al
possibl
contribut
mutant
swarm
facilit
prevent
domin
drugresist
mutant
infect
patient
still
larg
unexplor
difficult
anticip
three
type
barrier
list
box
may
result
level
drug
resist
particular
viru
particular
host
individu
specif
target
organ
given
time
addit
influenc
drug
pharmacokinet
drug
penetr
differ
cell
tissu
organ
viru
replic
see
fig
prior
histori
viru
replic
infect
host
surpris
studi
drug
resist
virus
remain
fundament
descript
independ
amino
acid
substitut
lead
resist
drug
altern
evolutionari
pathway
may
follow
depend
trna
abund
mutat
prefer
rel
nucleotid
substrat
concentr
viru
replic
site
resist
requir
two
amino
acid
substitut
genet
barrier
correspondingli
increas
section
box
quantif
barrier
resist
experi
cell
cultur
requir
prior
character
drug
test
act
cell
cultureadapt
viru
infect
specif
cell
line
two
basic
paramet
determin
toxic
drug
host
cell
capac
inhibit
product
infecti
viru
toxic
quantifi
concentr
drug
kill
given
percentag
gener
sometim
anoth
valu
cell
condit
use
infect
express
cytotox
concentr
cc
depict
fig
toxic
may
depend
cell
concentr
extent
confluenc
cell
monolay
metabol
state
cell
rest
vs
activ
divid
capac
inhibit
quantifi
concentr
inhibitor
reduc
infecti
progeni
product
given
percentag
gener
sometim
anoth
valu
defin
condit
infect
includ
multipl
infect
moi
express
inhibitori
concentr
ic
depict
fig
therapeut
index
ti
given
quotient
cc
ic
although
gener
use
vivo
experi
drug
efficaci
test
also
appli
cell
cultur
measur
three
paramet
cc
ic
ti
univers
viru
drug
sinc
may
influenc
composit
viral
popul
environment
factor
repeatedli
express
featur
virus
present
book
guid
ti
valu
suggest
excel
perform
antivir
agent
valu
higher
ten
accept
valu
lower
ten
predict
limit
efficaci
quantit
effect
drug
may
vari
analyz
singl
round
infect
versu
multipl
round
serial
passag
compar
vivo
versu
cell
cultur
experi
cc
ic
valu
serv
guid
decid
rang
drug
concentr
use
serial
passag
experi
evalu
possibl
select
inhibitorresist
mutant
estim
genet
barrier
possibl
overcom
genet
barrier
depend
viru
popul
size
virus
replic
cell
cultur
possibl
estim
minim
viral
popul
size
need
select
drugresist
mutant
gener
posit
correl
genet
barrier
fig
hypothet
exampl
figur
viral
popul
compos
inhibitorsensit
virus
blue
sphere
low
level
inhibitorresist
virus
red
sphere
proport
inhibitorresist
virus
given
mutat
pressur
eg
frequenc
increas
pictur
clariti
passag
small
amount
viru
eg
infecti
viru
small
circl
upper
part
figur
exclud
mutant
viru
red
sphere
maintain
basal
level
dictat
mutat
pressur
cours
passag
limit
two
figur
simplic
select
escap
mutant
preclud
limit
popul
size
transfer
contrast
popul
size
use
success
infect
suffici
larg
larger
circl
bottom
surround
sensit
resist
virus
resist
mutant
becom
figur
schemat
represent
two
experi
determin
concentr
inhibitor
need
kill
cell
cultur
cc
valu
left
concentr
inhibitor
reduc
viral
product
ic
valu
right
therapeut
index
quotient
cc
ic
box
bottom
similar
test
perform
tissu
explant
anim
control
environment
condit
see
text
pharmacolog
implic
resist
antivir
inhibitor
gradual
domin
isol
studi
give
anoth
exampl
singl
amino
acid
replac
requir
two
mutat
chang
cag
aug
attain
substitut
revers
transcriptas
associ
resist
multipl
antiretrovir
nucleosid
occur
lower
frequenc
replac
requir
singl
mutat
two
mutat
reach
frequenc
expect
frequenc
drugresist
genom
ignor
fit
effect
thu
least
viral
genom
must
undergo
one
round
copi
lower
number
genom
proport
higher
number
round
copi
approach
good
probabl
obtain
drugresist
genom
viral
popul
popul
size
limit
drug
select
event
specif
exampl
random
event
may
interven
process
posit
select
compar
section
fig
chapter
figur
random
event
exclud
posit
select
popul
conceptu
equival
insuffici
popul
size
depict
upper
infect
seri
fig
two
mutat
need
confer
resist
phenotyp
drug
resist
less
like
due
lower
probabl
gener
two
requir
mutat
also
increas
chanc
two
mutat
genom
entail
fit
cost
viru
requir
three
mutat
overcom
select
constraint
may
occur
frequenc
rang
lower
often
insuffici
mutant
present
mutant
spectrum
infect
host
fig
failur
select
drugresist
mutant
cell
cultur
necessarili
mean
resist
mutant
present
popul
may
mean
due
high
genet
barrier
select
experi
design
infect
insuffici
amount
viru
similar
even
accentu
problem
encount
select
experi
vivo
sinc
phenotyp
barrier
fit
cost
inflict
drugresist
mutat
box
often
estim
empir
frequenc
relev
substitut
patient
treat
drug
cell
cultur
assay
adequ
procedur
quantifi
phenotyp
barrier
resist
determin
fit
viru
express
protein
wildtyp
amino
acid
one
confer
drug
sensit
rel
viru
express
protein
substitut
amino
acid
confer
resist
fit
measur
absenc
presenc
drug
doubl
assay
extens
determin
fit
vector
describ
section
chapter
depict
fig
assay
best
perform
cell
cultur
although
use
explant
vivo
assay
also
feasibl
two
paramet
calcul
fit
cost
inflict
amino
acid
substitut
associ
resist
absenc
drug
reflect
fit
valu
f
drug
rel
wild
type
select
advantag
confer
substitut
presenc
drug
reflect
fit
valu
f
drug
rel
wild
type
lower
valu
f
drug
higher
fit
cost
defin
select
strength
resist
mutat
f
drug
f
drug
exampl
put
arbitrari
number
unrel
valu
shown
ordin
fit
valu
first
graph
fig
figur
decreas
frequenc
fit
mutant
genom
resist
one
two
three
inhibitor
genom
frequenc
level
decreas
sever
order
magnitud
resist
one
inhibitor
red
asterisk
upper
mutant
spectrum
two
inhibitor
red
green
asterisk
middlemut
spectrum
three
inhibitor
red
green
blue
asterisk
bottom
mutant
spectrum
must
occur
genom
left
part
figur
numer
valu
center
increas
number
mutat
gener
impli
fit
decreas
right
part
figur
see
text
implic
resist
antivir
inhibitor
f
drug
f
drug
obtain
select
strength
vector
second
graph
f
drug
f
drug
select
strength
high
select
strength
mean
import
select
advantag
confer
amino
acid
substitut
viru
replic
presenc
drug
despit
high
fit
cost
inflict
substitut
compar
section
chapter
tradeoff
free
lunch
concept
substitut
entail
fit
cost
f
drug
fit
valu
presenc
drug
equal
select
strength
select
strength
calcul
mutat
group
mutat
confer
resist
drug
use
given
concentr
defin
environ
exampl
de
la
higuera
et
al
limit
fit
measur
environ
depend
etc
describ
section
chapter
appli
sinc
viral
genom
sequenc
may
vari
cours
fit
assay
limit
number
passag
triplic
parallel
assay
recommend
substitut
entail
high
fit
cost
direct
revers
substitut
incorpor
compensatori
mutat
may
occur
nucleotid
sequenc
monitor
cours
assay
reinforc
conclus
drugresist
mutat
inflict
fit
cost
upon
viru
yet
rare
drug
resist
repres
unsurmount
barrier
maintain
viral
infect
sever
possibl
account
pertinaci
occurr
select
drugresist
viabl
viral
mutant
one
possibl
support
experiment
clinic
observ
drugresist
phenotyp
may
achiev
number
altern
genet
modif
even
specif
amino
acid
substitutiondthat
would
serv
direct
effect
determin
drug
resistancedwer
highli
detriment
lethal
viru
altern
mutat
often
found
lead
similar
resist
phenotyp
least
suffici
resist
permit
viru
replic
explor
sequenc
space
find
compensatori
mutat
connect
among
point
sequenc
space
fact
sever
space
posit
map
similar
drugresist
phenotyp
contribut
extend
occurr
drug
resist
phenotyp
redund
appli
standard
nonmutagen
inhibitor
mutagen
inhibitor
cascad
mutat
confer
resist
picornavirus
mutagen
purin
analog
ribavirin
illustr
altern
amino
acid
substitut
viral
polymeras
genuin
resist
mutat
other
act
compensatori
substitut
maintain
polymeras
function
lead
ribavirinresist
phenotyp
discuss
chapter
specul
interpret
systemat
occurr
drugresist
viral
mutant
major
chemic
use
antivir
therapi
fig
structur
may
relat
natur
compound
virus
ancestr
replic
machineri
encount
continu
struggl
surviv
view
drug
resist
would
gradual
built
consequ
coevolut
section
chapter
viru
replic
gene
express
machineri
space
chemic
compound
interact
mechan
drug
resist
might
root
molecular
event
repeatedli
experienc
virus
evolv
interact
manner
protocellular
cellular
metabolit
biospher
discrimin
favor
small
molecul
substrat
compat
flow
genom
replic
gene
express
avoid
perturb
intrud
could
alter
catalyt
activ
posit
select
unfortun
possibl
never
abl
test
whatev
reason
behind
unfortun
realiti
drug
resist
extrem
frequent
event
complic
enorm
control
viral
diseas
multipl
drug
evas
mechan
identifi
propos
rna
dna
virus
oper
depend
basic
replic
paramet
connect
drug
level
variat
time
delay
lysi
bacteriophag
reduc
replic
round
presenc
fu
produc
resist
analog
pereirag
omez
sanju
line
synchron
viru
life
cycl
replic
occur
drug
level
minim
propos
potenti
resist
mechan
neagu
et
al
viru
plastic
favor
modif
life
cycl
paramet
viru
surviv
presenc
drug
provid
time
relev
select
event
allow
treatment
implement
great
major
inhibitorresist
mechan
involv
amino
acid
substitut
viral
protein
directli
indirectli
diminish
bind
drug
viral
target
follow
major
mechan
document
substitut
protein
target
drug
decreas
affin
protein
drug
mutat
modifi
nucleotid
select
viral
polymeras
belong
group
substitut
may
affect
neighborhood
polymeras
catalyt
site
polymeras
domain
even
nonstructur
protein
interact
polymeras
inhibitor
act
viral
protein
viral
protein
genom
structur
target
amino
acid
substitut
mutat
affect
target
may
also
contribut
resist
correl
mutat
molecular
mechan
antivir
resist
first
second
target
may
also
yield
resist
phenotyp
case
proteas
inhibitorresist
mutat
case
viral
polymeras
mutat
permit
excis
chaintermin
nucleotid
end
primer
achiev
phosphorolysi
mediat
pyrophosph
donor
probabl
atp
resist
nucleosidenucleotid
revers
transcriptas
rt
inhibitor
nrti
achiev
one
least
two
mechan
discrimin
incorpor
triphosph
form
nrti
ii
excis
chaintermin
nucleotid
incorpor
end
grow
dna
chain
occur
thymidin
analog
resist
mutat
tam
typic
select
treatment
azt
formula
fig
group
amino
acid
substitut
may
yield
multidrugresist
phenotyp
wellstudi
exampl
complex
revers
transcriptas
includ
substitut
phenotyp
consist
limit
incorpor
sever
nucleotid
analog
mutant
character
decreas
catalyt
rate
constant
k
pol
incorpor
analog
analog
rel
standard
nucleotid
see
section
chapter
basic
kinet
paramet
polymeras
activ
combin
enzymolog
structur
studi
provid
molecular
interpret
mechan
inhibit
nrti
review
men
endezaria
men
endezaria
alvarez
clutter
et
al
unthard
et
al
predict
model
includ
nucleotid
level
see
von
kleist
et
al
nonnucleosid
rt
inhibitor
nnrti
bind
rt
pocket
away
consider
distanc
catalyt
site
compos
residu
subunit
enzym
hydrophob
natur
nnrti
illustr
fig
structur
nevirapin
efavirenz
delavirdin
formula
respect
sever
mechan
propos
explain
inhibitori
activ
includ
alter
catalyt
amino
acid
ymdd
rt
activ
site
distort
nucleotidebind
site
modif
posit
primer
receiv
incom
nucleotid
men
endezaria
amino
acid
substitut
confer
resist
nnrti
block
access
inhibitor
bind
site
alter
conform
volum
bind
pocket
essenti
viral
proteas
target
develop
specif
antivir
inhibitor
exampl
saquinavir
ritonavir
formula
respect
fig
multipl
resist
mutat
describ
proteas
inhibitor
affect
substratebind
site
neighbor
posit
often
accompani
compensatori
substitut
distant
posit
includ
site
target
viral
protein
eg
gag
cleavag
site
fun
et
al
flynn
et
al
proteas
inhibitor
combin
display
high
genet
barrier
resist
significantli
capac
virus
explor
sequenc
space
resist
mutant
amino
acid
substitut
proteasecod
region
isol
rhee
et
al
review
men
endezaria
men
endezaria
alvarez
provid
excel
detail
account
mechan
resist
inhibitor
includ
viru
entri
integras
inhibitor
addit
rt
proteas
inhibitor
briefli
describ
quasispeci
dynam
diseas
prevent
control
distanc
effect
exert
among
amino
acid
structur
protein
substitut
confer
resist
inhibitor
viral
enzym
may
lie
far
catalyt
site
effect
drugresist
mutat
gener
catalyt
effici
viral
enzym
one
determin
function
barrier
resist
sinc
may
diminish
replic
fit
enzym
activ
assay
vitro
avail
effect
specif
drugresist
amino
acid
substitut
enzym
activ
test
although
observ
alter
may
influenc
fit
modif
correspond
mutant
viru
reason
viral
protein
includ
viral
enzym
multifunct
enzym
activ
assay
may
captur
rang
influenc
exert
enzym
regard
directact
antivir
daa
agent
hcv
inhibitor
target
hcv
polymeras
gener
display
higher
function
barrier
resist
proteas
inhibitor
manifest
broader
genotyp
coverag
fit
decreas
entail
reduct
viral
load
consequ
lower
probabl
viral
breakthrough
treatment
failur
nucleotid
analog
bind
conserv
residu
near
activ
site
viral
polymeras
tend
show
subtypeindepend
antivir
activ
amino
acid
substitut
near
activ
site
viral
enzym
like
inflict
fit
cost
substitut
may
preexist
treatmentna
patient
margeridonthermet
shafer
sarrazin
zeuzem
interestingli
case
mutat
confer
resist
rt
inhibitor
inflict
lower
fit
cost
mutat
confer
resist
proteas
inhibitor
review
martinezpicado
martinez
thu
enzym
perform
similar
function
differ
virus
may
evolv
display
differ
toler
amino
acid
substitut
possibl
gener
type
resist
mutat
display
high
low
function
barrier
broad
rang
frequenc
antibodyand
drugescap
mutant
viral
popul
although
valu
mutant
per
infecti
unit
frequent
mani
rna
dna
virus
see
tabl
chapter
antibodyescap
mutant
estim
drugescap
mutant
list
tabl
sever
observ
character
escap
mutant
accompani
frequenc
measur
point
worth
emphas
quantif
virus
harbor
biolog
relev
mutat
possibl
adequ
biolog
assay
avail
antivir
agent
neutral
antibodi
measur
proport
infecti
viral
particl
differ
major
popul
relev
resist
trait
reason
suspect
viral
amino
acid
residu
target
inhibitor
antibodi
substitut
confer
resist
phenotyp
prone
accept
variat
mani
amino
acid
viral
protein
addit
select
agent
probe
viral
site
expect
similar
rang
variant
amino
acid
use
inhibitor
antibodi
quit
straightforward
predict
anoth
way
state
gener
agreement
mutat
rate
frequenc
virus
rang
substitut
per
nucleotid
snt
calcul
use
varieti
biochem
genet
method
chapter
quit
gener
observ
antibodi
neutral
experi
fraction
viru
popul
remain
infecti
despit
molecular
mechan
antivir
resist
addit
high
antibodi
concentr
although
resist
mechan
unclear
possibl
heterogen
viral
popul
includ
small
proport
antigen
variant
decreas
affin
antibodi
incomplet
neutral
nonsigmoid
slope
neutral
curv
character
broadli
neutral
antibodi
direct
mccoy
et
al
gener
observ
ad
complic
prevent
design
consid
administr
neutral
antibodi
either
vaccin
addit
combin
antivir
inhibitor
section
chapter
calcul
frequenc
antibodyor
drugresist
mutant
viral
popul
may
lower
rate
origin
mutat
due
fit
cost
mutat
section
argument
parallel
use
justifi
mutat
rate
frequenc
differ
due
fit
effect
mutat
chapter
anoth
predict
deriv
consider
mutat
confer
resist
antivir
agent
expect
detect
viral
popul
never
expos
relev
drug
form
genet
variat
virus
contribut
domin
spread
drugresist
mutant
includ
combin
effect
mutat
recombin
genom
segment
reassort
richman
neher
leitner
roger
et
al
basal
level
mutat
pressur
may
suffici
provid
detect
proport
escap
mutant
without
need
select
select
agent
import
aspect
antivir
therapi
address
next
first
demonstr
baselin
mutat
level
viral
quasispeci
includ
detect
level
mutat
confer
resist
inhibitor
absenc
select
inhibitor
obtain
dd
ho
n
ajera
c
l
colleagu
work
mohri
et
al
n
ajera
et
al
one
studi
examin
pol
gene
genom
obtain
directli
lymphocyt
infect
patient
mutat
frequenc
independ
viral
isol
egger
tamm
amantadin
rimantadin
iv
measur
cell
cultur
appleyard
lubeck
et
al
rimantadin
iv
percentag
children
treat
rimantadin
shed
resist
iv
belsh
et
al
disoxaril
lowlevel
resist
cell
cultur
heinz
et
al
highlevel
resist
cell
cultur
guanidin
pv
measur
cell
cultur
pincu
wimmer
formula
drug
includ
figur
follow
number
parenthesi
amantadin
rimantadin
disoxaril
rang
snt
mutant
spectrum
compon
individu
isol
valu
snt
viru
patient
mutat
frequenc
codon
amino
acid
involv
antiretrovir
resist
similar
averag
mutat
frequenc
entir
pol
gene
consist
mutat
frequenc
valu
sever
mutat
led
amino
acid
substitut
confer
resist
revers
transcriptas
inhibitor
identifi
patient
subject
therapi
time
studi
number
antiretrovir
agent
still
limit
consider
number
patient
treat
author
gave
convinc
epidemiolog
argument
background
mutat
relat
antiretrovir
resist
consequ
high
mutat
rate
quasispeci
dynam
due
transmiss
resist
viru
individu
subject
therapi
primari
resist
n
ajera
et
al
presenc
inhibitorresist
mutat
viral
popul
never
expos
correspond
inhibitor
confirm
sever
virus
includ
hcv
support
calcul
mutant
frequenc
viral
quasispeci
havlir
et
al
lech
et
al
ribeiro
et
al
ribeiro
bonhoeff
cubero
et
al
johnson
et
al
toni
et
al
tsibri
et
al
peresdasilva
et
al
ampl
support
also
come
deep
sequenc
analys
mutant
spectra
open
point
debat
basal
frequenc
inhibitorresist
mutat
constitut
indic
avoid
use
correspond
inhibitor
therapi
least
case
hcv
probabl
applic
virus
basi
suggest
presenc
drug
resist
mutat
certain
level
patient
relev
treatment
failur
inhibitor
administ
understand
quasispeci
dynam
caution
reductionist
argument
evidenc
clinic
case
peral
et
al
data
underlin
relev
mutant
spectra
phenotyp
reservoir
confront
select
constraint
constraint
oper
treatment
includ
drug
alreadi
administ
patient
past
influenc
quasispeci
memori
also
consid
section
chapter
mutant
spectra
view
anticipatori
reservoir
phenotyp
addit
presenc
drug
resist
mutat
viral
popul
due
mutant
frequenc
level
transmiss
drugresist
mutant
treat
na
ive
patient
may
contribut
epidemiolog
relev
resist
mutat
primari
resist
ampli
document
appear
increas
case
hcv
franco
et
al
et
al
huang
et
al
higher
level
resist
mutat
function
time
untreat
patient
indic
mutat
due
basal
mutant
frequenc
epidemiolog
expans
viru
mutant
origin
treat
patient
clinic
data
avail
rate
expans
viru
harbor
resist
mutat
may
vari
depend
transmiss
epidemiolog
featur
pathogen
seem
unavoid
face
extend
treatment
genet
variabl
pathogen
virus
confront
situat
parallel
antibiot
resist
bacteria
chapter
major
mechan
drug
resist
virus
base
amino
acid
substitut
render
drug
ineffect
sever
molecular
mechan
summar
section
applic
cell
cultur
system
hcv
replic
human
hepatoma
cell
lindenbach
et
al
wakita
et
al
zhong
et
al
examin
effect
fit
fitnessassoci
trait
multidrugresist
mechan
longterm
evolut
indic
viral
fit
addit
mechan
drug
resist
evid
obtain
address
import
issu
hcv
resist
interferonalpha
ifna
ifna
ribavirin
two
compon
standard
care
treatment
hcv
infect
advent
new
therapi
base
daa
agent
natur
hcv
isol
differ
ifna
sensit
molecular
basi
differ
larg
unknown
studi
cell
cultur
consist
subject
clonal
popul
hcv
term
prepar
electropor
hepatoma
cell
rna
encod
viral
genom
transcrib
plasmid
serial
passag
type
describ
section
chapter
absenc
presenc
increas
concentr
ifna
ad
cultur
medium
sever
mutat
scatter
throughout
hcv
genom
associ
ifna
resist
peral
et
al
select
multipl
altern
mutat
like
influenc
fact
ifna
evok
multicompon
antivir
respons
focus
toward
singl
viral
protein
peral
et
al
unexpectedli
even
control
hcv
popul
passag
time
absenc
ifna
display
partial
statist
signific
resist
ifna
could
attribut
endogen
ifn
product
hepatoma
cell
peral
et
al
view
intrigu
result
initi
popul
hcv
popul
passag
time
absenc
ifna
term
respect
test
resist
inhibitor
hcv
replic
proteas
inhibitor
telaprevir
formula
fig
inhibitor
daclatasvir
cellular
protein
cyclophilin
inhibitor
cyclosporin
mutagen
purin
nucleosid
ribavirin
high
barrier
inhibitor
sofosbuvir
formula
fig
display
significantli
increas
resist
inhibitor
test
compar
parent
popul
gallego
et
al
fig
passag
hcv
entail
increas
viral
fit
broaden
mutant
spectrum
might
increas
frequenc
mutat
associ
drug
resist
thu
explain
behavior
multipli
passag
hcv
popul
search
resist
mutat
easier
telaprevir
daclatasvir
cyclosporin
drug
amino
acid
substitut
target
protein
previous
identifi
respons
drug
resist
case
cyclosporin
resist
substitut
map
drug
bind
cyclophilin
turn
interact
analysi
mutant
spectra
molecular
clone
sanger
sequenc
deep
sequenc
fail
identifi
specif
drugresist
mutat
sinc
could
exclud
broaden
mutant
spectrum
might
increas
frequenc
resist
mutat
still
character
two
addit
test
perform
one
determin
kinet
viral
product
rang
moi
absenc
presenc
telaprevir
unpassag
multipli
passag
hcv
display
parallel
kinet
differ
moi
exclud
drug
resist
due
presenc
resist
mutat
minor
compon
mutant
spectrum
fig
substanti
find
biolog
clone
obtain
endpoint
dilut
correspond
popul
test
regard
drug
resist
biolog
clone
elimin
minor
genom
harbor
drugresist
mutat
sinc
biolog
clone
sever
form
bottleneck
event
section
chapter
biolog
clone
display
decreas
drug
resist
compar
quasispeci
dynam
diseas
prevent
control
moreno
e
gallego
pineiro
et
al
increas
replic
fit
lead
decreas
drug
sensit
hepat
c
viru
j
virol
permiss
american
societi
microbiolog
washington
dc
usa
fit
fitnessassoci
trait
multidrugresist
mechan
correspond
parent
unclon
popul
observ
establish
viral
fit
multidrugresist
determin
hcv
may
also
appli
virus
one
possibl
molecular
mechan
may
consist
competit
replic
complex
inhibitori
molecul
insid
infect
cell
model
impli
fit
increas
reflect
either
replic
molecul
per
replic
unit
increas
number
replic
unit
per
cell
without
influenc
number
inhibitor
molecul
reach
replic
site
explor
competit
model
altern
model
extens
viralhost
system
import
challeng
field
antivir
research
sum
mutant
spectra
quasispeci
dynam
mediat
antivir
resist
least
two
mechan
increas
proport
resist
mutat
mutant
spectra
ii
fit
increas
promot
continu
viral
replic
environ
mechan
may
act
conjointli
viral
infect
vivo
studi
hcv
document
drugresist
phenotyp
infect
patient
absenc
specif
drugresist
mutat
sullivan
et
al
svarovskaia
et
al
sato
et
al
stross
et
al
di
maio
et
al
dietz
et
al
fact
prolong
chronic
hcv
infect
repres
adequ
scenario
fit
increas
due
extend
round
infect
host
liver
consequ
chronic
infect
may
prone
display
fitnessassoci
multidrugresist
phenotyp
absenc
drugresist
mutat
multipl
mechan
drug
resist
relat
quasispeci
dynam
justifi
even
need
new
antivir
strategi
present
chapter
high
viral
load
predictor
diseas
progress
lentivirus
effici
earli
control
viru
replic
host
immun
respons
gener
associ
limit
diseas
sever
viral
load
follow
initi
immun
respons
refer
viral
set
point
absenc
earli
therapi
low
set
point
gener
attribut
strong
cellular
immun
respons
like
influenc
addit
host
viral
factor
aspect
replic
pathogenesi
review
excel
monograph
levi
levi
low
set
point
predict
asymptomat
outcom
gener
case
virus
establish
persist
rather
acut
infect
high
viral
fit
earli
stage
viral
replic
promot
diseas
manifest
suggest
progress
toward
diseas
cohort
individu
infect
blood
transfus
contain
larg
delet
nef
adaptor
protein
mediat
replic
pathogenesi
review
arien
verhasselt
year
infect
individu
show
clinic
sign
probabl
result
accumul
mutat
genom
compens
lack
nef
gener
fitnessdecreas
lethal
genet
lesion
viral
genom
may
compens
addit
genom
mutat
becom
increasingli
domin
cours
viral
replic
kinet
fit
gain
depend
natur
lesion
function
implic
alter
protein
genom
regulatori
region
chapter
fit
replic
capac
viral
load
directli
interconnect
paramet
quasispeci
dynam
diseas
prevent
control
affect
diseas
progress
domingo
et
al
fig
fit
gain
effect
high
load
activ
replic
viru
infect
organ
elev
replic
capac
fit
sustain
high
viral
load
reason
basic
featur
viral
popul
dynam
given
basal
mutat
rate
larg
number
replic
genom
entail
correspondingli
higher
probabl
requir
mutat
fit
gain
produc
event
involv
specif
case
search
adapt
mutat
term
explor
sequenc
space
discuss
section
chapter
activ
viral
replic
high
load
high
fit
favor
progress
infect
diseas
manifest
fourth
paramet
includ
larg
arrow
fig
mutant
spectrum
divers
optim
rang
low
high
intrapopul
divers
detriment
viru
adapt
insuffici
divers
limit
adapt
complex
environ
pfeiffer
kirkegaard
vignuzzi
et
al
excess
divers
may
lead
viru
cross
extinct
threshold
basi
lethal
mutagenesi
antivir
therapi
chapter
addit
implic
paramet
shown
fig
antivir
intervent
fit
decreas
recogn
altern
inhibit
viral
replic
control
viral
infect
clementi
clementi
lazzarin
review
domingo
et
al
thu
key
featur
quasispeci
dynam
direct
implic
manag
viral
infect
extern
intervent
appli
envisag
limit
suppress
viru
infect
includ
vaccin
administr
antivir
agent
describ
previou
section
also
passiv
immunotherapi
antisens
rna
oligonucleotid
variou
chemic
modif
interf
rna
ribozym
combin
biotechnolog
develop
favor
design
chemic
defin
vaccin
consist
express
immunogen
protein
synthet
peptid
peptid
array
without
need
handl
administ
live
viru
one
na
ive
manifest
trust
biotechnolog
middl
centuri
belief
catalog
plasmid
encod
antigen
protein
circul
type
pathogen
virus
would
suffic
prepar
requir
vaccin
need
concern
influenza
vaccin
wi
beveridg
wrote
follow
first
object
would
captur
full
rang
influenza
subtyp
antigen
would
studi
specialist
central
laboratori
made
avail
prepar
particular
vaccin
requir
might
feasibl
stockpil
vaccin
princip
hemagglutinin
antigen
use
figur
schemat
represent
interconnect
paramet
viral
replic
often
relat
diseas
progress
understand
quasispeci
dynam
made
evid
aim
antivir
therapi
need
directli
diminish
viral
load
also
affect
paramet
reduc
viral
load
see
text
justif
refer
chapter
new
antivir
strategi
follow
concept
express
figur
limit
simplifi
reagent
small
molecul
antivir
agent
fire
brigad
type
action
soon
incipi
pandem
spot
beveridg
naiveti
also
perceiv
current
design
univers
vaccin
base
conserv
antigen
consid
differ
escap
mechan
oper
virus
elud
neutral
antibodi
chai
et
al
remark
present
understand
viral
popul
render
obsolet
view
express
wi
beveridg
book
write
boom
implement
dna
recombin
techniqu
yet
attempt
produc
vaccin
highli
variabl
virus
base
antigen
structur
viral
isol
ongo
christiansen
et
al
critic
issu
host
immun
respons
vaccin
engin
univers
conserv
antigen
motif
suffici
prevent
diseas
upon
infect
form
pathogen
freeman
cox
current
knowledg
viral
popul
dynam
seem
unlik
time
tell
sinc
effort
toward
manufactur
univers
antivir
vaccin
way
conceptu
similar
vaccin
medic
practic
monotherapi
antivir
agent
tradit
prefer
drug
mixtur
chang
paradigm
larg
consequ
aid
epidem
publicli
express
pioneer
hepatologist
sherlock
summari
address
intern
symposium
viral
hepat
held
madrid
chang
perspect
clear
antivir
strategi
antisens
nucleic
acid
virusdirect
ribozym
intens
investig
decad
ago
unlik
use
isol
convert
use
antivir
therapi
resist
mutant
like
select
yet
could
part
combin
antivir
inhibitor
provid
larger
antivir
barrier
chapter
similar
fate
like
interf
rna
boden
et
al
gitlin
et
al
herreracarrillo
berkhout
mcdonagh
et
al
larg
extent
failur
defin
chemic
entiti
oligonucleotid
ribozym
small
molecul
inhibitor
etc
control
viru
replic
spread
consequ
target
defin
viral
genom
sequenc
combin
adapt
viral
popul
combin
multipl
element
envisag
test
offtarget
effect
adapt
potenti
virus
like
limit
efficaci
unfortun
biotechnolog
develop
posit
mani
research
area
practic
applic
tend
simplifi
type
agent
prevent
diseas
inhibit
viru
replic
ignor
inher
complex
object
control
success
unlik
complex
combat
simplic
increas
understand
viral
popul
dynam
last
decad
chang
pictur
dramat
provid
interpret
viru
escap
gener
larg
unavoid
phenomenon
awar
push
develop
new
antivir
design
fundament
center
two
strategi
combin
multipl
independ
act
element
fit
decreas
excess
mutat
chapter
pronounc
p
ehrlich
intern
congress
medicin
held
london
reflect
old
tradit
treat
microbi
infect
therefor
old
therapeut
motto
applic
frapper
fort
et
frapper
vitt
therefor
opinion
necessari
allow
therapeut
treatment
come
action
earli
possibl
sentenc
taken
ehrlich
emphas
origin
text
pronounc
fit
current
understand
viral
popul
follow
ehrlich
full
implic
quasispeciesmedi
adapt
virus
quasispeci
dynam
diseas
prevent
control
antivir
therapi
express
dd
ho
influenti
articl
entitl
time
hit
hiv
earli
hard
ho
articl
titl
captur
need
prevent
adapt
viru
infect
host
opportun
replic
exploit
viru
increas
fit
becom
less
vulner
intern
intrahost
extern
intervent
antivir
therapi
treatment
interrupt
chronic
infect
drug
holiday
case
patient
justifi
allevi
side
effect
associ
administr
antiretrovir
agent
provid
opportun
viru
gain
fit
principl
given
current
understand
viral
quasispeci
dynam
propos
p
ehrlich
dd
ho
applic
viral
pathogen
one
argument
tone
strength
hit
earli
hit
hard
propos
infect
patient
may
progress
diseas
maintain
asymptomat
lifelong
persist
infect
case
elit
control
case
infect
individu
infect
hcv
progress
toward
liver
diseas
case
nonprogress
anticip
viral
host
paramet
may
justifi
exclud
patient
aggress
intervent
suthar
harri
casado
et
al
gener
rule
howev
potenti
benefit
earli
treatment
obviou
avoid
diseas
individu
basi
also
diminish
chanc
viru
transmiss
review
suthar
harri
see
also
section
chapter
regard
relev
viral
popul
number
transmiss
restrict
number
treat
patient
econom
reason
result
expens
public
health
intervent
infect
individu
develop
diseas
box
includ
recommend
use
antivir
agent
recapitul
concept
explain
preced
section
despit
emphasi
evolutionari
aspect
prevent
treatment
viral
diseas
mani
angl
box
avoid
monotherapi
ideal
use
two
antivir
agent
share
mechan
action
fig
treat
soon
possibl
viru
diagnosi
avoid
viru
adapt
associ
high
viru
popul
size
minim
transmiss
inhibitorresist
mutant
individu
patient
treat
time
drug
prove
effect
viral
load
rebound
treatment
discontinu
use
deep
sequenc
methodolog
determin
mutant
spectrum
composit
adequ
choic
inhibitor
aim
design
person
treatment
consid
probabl
drug
combin
efficaci
minim
side
effect
consid
temporari
shelv
effect
drug
resist
mutant
acquir
epidemiolog
relev
consid
chapter
connect
factor
diseas
emerg
smolinski
et
al
three
mention
import
adequ
treatment
design
describ
chapter
adequaci
public
health
measur
ii
public
inform
viru
sourc
mean
contagion
iii
need
global
polit
action
inform
public
aim
limit
spread
diseas
undertak
person
collect
action
reduc
r
valu
given
viru
chapter
section
illustr
key
point
quit
extens
inform
campaign
aid
develop
countri
earli
decad
spread
inform
potenti
threaten
virus
ebola
sever
acut
middl
east
respiratori
syndrom
sar
mer
respect
coronavirus
limit
need
global
respons
limit
extens
diseas
episod
site
initi
recogn
long
time
becam
obviou
west
african
ebola
epidem
see
siedner
et
al
need
intern
organ
govern
develop
countri
provid
healthcar
workforc
assist
lowand
middleincom
countri
control
viral
episod
earli
stage
help
earli
help
effect
recogn
need
global
scale
parallel
hit
earli
hit
hard
treatment
infect
patient
global
earli
action
adequ
inform
import
adequ
treatment
design
control
viral
diseas
restrict
viral
replic
round
consequ
adapt
inform
thought
critic
control
ebola
epidem
nigeria
siedner
et
al
howev
inform
must
also
plan
reach
target
popul
convinc
manner
learn
polioviru
vaccin
erad
campaign
renn
uncertainti
regard
whether
initi
limit
episod
viral
diseas
expand
die
help
decis
make
howev
best
choic
case
emerg
reemerg
infect
act
assum
worst
scenario
medic
intervent
repres
total
new
set
select
constraint
virus
face
sinc
decad
ago
infinitesim
time
exist
biolog
entiti
howev
evolutionari
mechan
avail
virus
success
cope
mani
select
pressur
notabl
effect
vaccin
broad
immun
respons
evok
treatment
antivir
agent
common
way
proceed
test
new
vaccin
anim
host
authent
host
anim
model
obtain
full
protect
anim
challeng
viru
match
antigen
composit
vaccin
follow
initi
excit
often
vaccin
display
partial
protect
test
natur
environ
somewhat
parallel
argument
made
clinic
trial
antivir
agent
usual
perform
initi
select
group
patient
clinician
coin
term
reallif
treatment
studi
patient
select
optim
result
often
push
commerci
polit
interest
chapter
emphas
complex
viral
popul
seriou
often
underestim
difficulti
prevent
treat
viral
diseas
examin
molecular
mechan
exploit
virus
surviv
despit
antivir
intervent
suggest
two
major
line
action
first
judici
use
exist
tool
consid
complex
viral
popul
dynam
complex
quasispeci
dynam
diseas
prevent
control
combat
simplic
second
need
design
new
antivir
strategi
topic
address
chapter
sever
interconnect
paramet
determin
probabl
success
antivir
intervent
follow
gener
concept
darwinian
evolut
explain
preced
chapter
import
howev
quantifi
much
possibl
evolutionari
event
determin
therapi
success
failur
reason
import
viral
popul
size
basic
probabl
calcul
develop
resist
select
strength
mutat
explain
numer
exampl
hope
simpl
quantif
permit
higher
awar
treatment
may
succeed
fail
live
unequ
societi
chapter
close
recognit
mani
social
econom
issu
import
scientif
plan
combat
pathogen
virus
around
us
see
summari
box
medic
intervent
repres
new
class
select
constraint
act
viral
popul
viral
evolut
affect
antivir
prevent
treatment
strategi
two
differ
way
molecular
mechan
shortterm
respons
treat
individu
select
escap
mutant
ii
epidemiolog
impact
virus
acquir
escap
mutat
ineffect
vaccin
contribut
select
antigen
viral
variant
select
viral
mutant
resist
antivir
agent
gener
phenomenon
select
favor
suboptim
treatment
delay
combin
administr
multipl
inhibitor
resist
may
also
occur
absenc
specif
resist
mutat
associ
viral
fit
aim
therapi
increas
function
barrier
resist
give
opportun
viru
pursu
replic
increas
replic
fit
replic
rate
viral
load
fit
mutant
spectrum
complex
interconnect
paramet
may
tip
balanc
toward
either
control
infect
diseas
progress
paramet
target
antivir
design
health
care
resourc
adequ
public
inform
firm
polit
action
import
antivir
design
control
viru
infect
global
level
